Notch ligand Delta-like 1 promotes in vivo vasculogenesis in human cord blood-derived endothelial colony forming cells by Kim, Hyojin et al.
Notch ligand Delta-like 1 promotes in vivo vasculogenesis in 
human cord blood–derived endothelial colony forming cells
HYOJIN KIM1,2,3,4, LAN HUANG1,2,3,*, PAUL J. CRITSER1,2, ZHENYUN YANG1,2, REBECCA J. 
CHAN1,2, LIN WANG1,2,5, NADIA CARLESSO1,2,5, SHERRY L. VOYTIK-HARBIN6, IRWIN D. 
BERNSTEIN4, and MERVIN C. YODER1,2,3
1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
2Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, 
Indianapolis, Indiana, USA
3Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 
Indianapolis, Indiana, USA
4Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
5Department of Medical and Molecular Genetics, Indiana University School of Medicine, 
Indianapolis, Indiana, USA
6Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA
Abstract
 Background aims—Human cord blood (CB) is enriched in circulating endothelial colony 
forming cells (ECFCs) that display high proliferative potential and in vivo vessel forming ability. 
Because Notch signaling is critical for embryonic blood vessel formation in utero, we 
hypothesized that Notch pathway activation may enhance cultured ECFC vasculogenic properties 
in vivo.
 Methods—In vitro ECFC stimulation with an immobilized chimeric Notch ligand (Delta-
like1ext-IgG) led to significant increases in the mRNA and protein levels of Notch regulated Hey2 
and EphrinB2 that were blocked by treatment with γ-secretase inhibitor addition. However, Notch 
stimulated preconditioning in vitro failed to enhance ECFC vasculogenesis in vivo. In contrast, in 
vivo co-implantation of ECFCs with OP9-Delta-like 1 stromal cells that constitutively expressed 
the Notch ligand delta-like 1 resulted in enhanced Notch activated ECFC-derived increased vessel 
density and enlarged vessel area in vivo, an effect not induced by OP9 control stromal 
implantation.
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 Results—This Notch activation was associated with diminished apoptosis in the exposed 
ECFC.
 Conclusions—We conclude that Notch pathway activation in ECFC in vivo via co-implanted 
stromal cells expressing delta-like 1 promotes vasculogenesis and augments blood vessel 
formation via diminishing apoptosis of the implanted ECFC.
Keywords
apoptosis; endothelial colony forming cells (ECFCs); Notch ligand delta-like 1 (Dll1); OP9-Delta-
like 1 stromal cells (OP9-DL1); vasculogenesis
 Introduction
The Notch signaling pathway is an evolutionarily conserved pathway that is involved in a 
variety of developmental processes [1–3]. Notch family members and Notch ligands are 
expressed in endothelial cells (ECs) throughout early vascular development [4–6]. Notch 1, 
Notch 4, Jagged 2, delta-like 1 (Dll1) and 4 (Dll4) are specifically expressed in arterial 
endothelium [5,7], and these molecules play critical roles in arterial specification [8–13]. 
Vascular endothelial growth factor (VEGF) is one of the most potent and ubiquitous vascular 
growth factors that affect many aspects of EC biology. Recently, VEGF-A has been found to 
interact with the activated Notch pathway to determine and maintain arterial EC fate [13–
15]. Less is known of how Notch signaling may influence the vasculogenic properties of 
human vessel forming cells.
In Notch 1– and 4–deficient mouse embryos, embryos failed to remodel the plexus to form 
large and small blood vessels, although the primary vascular plexus appeared to form 
normally. This indicates that Notch signaling plays a critical role in angiogenic vascular 
morphogenesis and remodeling [16,17]. Different human EC lines have been studied the 
regulation of Notch signaling pathway in human vascular development. Most studies have 
used human umbilical vein endothelial cells (HUVECs) or human arterial/microvascular 
endothelial cells to investigate the roles of the Notch signaling pathway on their angiogenic 
and vasculogenic behavior. Notch 1 activation has been implicated both in promoting and in 
inhibiting cell death in a cell type specific manner [18–21]. Notch 1 activation in cultured 
monocytes plated upon immobilized Deltaext-myc has been reported to induce apoptosis [22]. 
On the other hand, activation of Notch 1 and a downstream mediator, HES1, in human iliac 
artery endothelial cells (HIAECs) caused growth suppression but improved cell survival of 
the cultured cells. Also, activated Notch 1 in HIAECs formed more stabilized network and 
cord formation on Matrigel substrate in the presence of VEGF [23]. Dll1-dependent Notch 
signaling mediated by Ephrin-B2 induced branching morphogenesis and network formation 
by human arterial endothelial cells (HAECs) plated on Matrigel [24]. These reports 
indicated that Notch 1 signaling plays a role in regulating endothelial cell survival and 
network and cord formation in vitro, but limited evidence has been presented to examine 
how in vitro Notch activation preconditioning might influence angiogenic or vasculogenic 
behavior when cells are implanted in vivo.
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We have successfully isolated circulating endothelial colony forming cells (ECFCs) from 
human umbilical cord blood (CB) and identified a hierarchy of proliferative potential in 
ECFC through the use of single-cell clonogenic and functional assays [25,26]. Human CB 
ECFCs form a human capillary plexus in immunodeficient mice after subcutaneous 
implantation in collagen-fibronectin gels and, upon inosculation with murine vessels, 
become a part of the systemic host circulation [26,27]. We have recently determined that all 
viable circulating ECFCs in human CB and adult peripheral blood can be enriched and 
identified as ECs expressing CD34, CD146, CD105 and CD31, but not CD45 or CD133 
[28]. These circulating viable endothelial cells represent those rare circulating ECFC that are 
known to colonize and re-endothealize implanted biomaterials in human subjects [29,30].
The use of circulating CB ECFCs to study human vessel formation within immunodeficient 
mice permits analysis of human vasculogenesis and determination of key regulatory 
molecules controlling human vessel formation in vivo in a unique model system. For 
example, use of cultured CB ECFC with adult bone marrow mesenchymal stromal cells 
(MSCs) can re-create a hematopoietic and leukemic stem cell niche in vivo [31]. Because 
Notch pathway activation plays such a key role in establishing the murine embryonic 
vascular system, we hypothesized that in vitro preconditioning of human CB ECFC with 
Notch ligand may enhance in vivo vasculogenic activity. We report that preconditioning of 
ECFC with Notch activation in vitro is insufficient to promote in vivo vasculogenesis; 
however, provision of the Notch ligand Dll1 by OP9 stromal cells in vivo activates Notch 1 
signaling in ECFC and enhances human blood vessel formation.
 Methods
 Media and supplements
Human Endothelial serum free medium (Invitrogen) was supplemented with 20 ng/mL 
human recombinant basic fibroblast growth factor (Invitrogen), 10 ng/mL human 
recombinant epidermal growth factor (R&D), 10 ng/mL human recombinant vascular 
endothelial growth factor 165 (rhVEGF-A/rhVEGF165; R&D), 10 ng/mL rhVEGF121 
(R&D), 10 ng/mL stem cell factor (R&D), 5 ng/mL stromal cell–derived factor 1alpha 
(R&D), 10 ng/mL interleukin 6 (IL6) (R&D) and 1.5% human cord plasma, to create serum 
reduced medium (SRM).
 Isolation and culture of human umbilical CB–derived ECFCs
Human umbilical CB samples (50–100 mL) were collected in heparin-coated syringes from 
healthy newborns (38–40 weeks’ gestation). The Institutional Review Board at Indiana 
University School of Medicine reviewed and approved this study with exempt status. 
Umbilical CB was diluted 1:1 with Dulbecco’s phosphate-buffered saline (PBS) (Invitrogen) 
and overlaid onto Ficoll-Paque PLUS (GE Healthcare). Cells were centrifuged for 30 min at 
room temperature at 1500 rpm. Mononuclear cells (MNCs) were isolated and washed with 
Dulbecco’s PBS. For outgrowth of ECFC colonies, MNCs were resuspended in SRM; 3×107 
MNCs were seeded onto each well of 6-well tissue culture plates pre-coated with type I rat-
tail collagen (BD Biosciences Pharmingen) and cultured as previously described [25]. ECFC 
colonies appeared at ~4 days of culture and were noted to form colonies of adherent cells 
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with cobblestone morphology. After ~10 days of culture, the ECFC-derived ECs were 
released from the culture dish by TrypLE Express (Gibco) and replated onto 25-cm2 tissue 
culture flasks pre-coated with type I rat-tail collagen for subsequent passage. 
Characterization of human umbilical CB ECFC–derived ECs was conducted using 
monoclonal antibodies and fluorescence-activated cell sorter analysis as previously 
described [25].
 Immobilization of Delta1ext-IgG protein
Delta1ext-IgG protein is the extracellular domain of human Dll1 fused to the Fc domain of 
human immunoglobulin (Ig)G1 [32]. Non-tissue culture-treated plates were coated with 
decreasing concentrations of Delta1ext-IgG (20, 10, 5, 2.5, 1.25, 0.625 and 0.3125 μg/mL) or 
the same concentration of human IgG (Sigma-Aldrich), diluted in PBS together with 5 
μg/mL fibronectin fragment CH-296 (Takara Shuzo). The plates were incubated overnight at 
4°C, washed with PBS 3 times and further incubated with 2% bovine serum albumin 
dissolved in PBS at 37°C for 1 h. Thereafter, plates were washed with PBS 3 times and were 
then ready for plating cells.
 RNA isolation and conventional/quantitative reverse transcriptase polymerase chain 
reaction
Total cellular RNA was extracted with an RNeasy Micro extraction kit (Qiagen) as described 
by the manufacturer. Reverse transcriptase (RT) reactions were performed using an 
Omniscript RT Kit (Qiagen). Conventional polymerase chain reaction (PCR) was conducted 
by using Go Tap Flexi DNA Polymerase (Promega) according to the manufacturer’s 
instructions. The primer sequences are shown in Table I. The PCR cycle profile was 94°C 
for 5 min; 94°C for 30 s, 53 or 57°C (depending on the different primers) for 30 s, 72°C for 
45 s, and 32 cycles with a final 72°C for 7 min. PCR products were added to wells in a 2% 
agarose/ethidium bromide gel and exposed to electrophoresis current. Migrating bands were 
photographed under ultraviolet light.
Quantitative PCR was performed using FastStart Universal SYBR green master 2× (Rox) 
(Roche). The relative standard curve of each gene amplification was first generated to 
determine the amplification efficiency (Eff). ATP5B was used as a housekeeping gene. To 
compare gene expression levels among treated and control ECFCs, results were presented as 
the ratio of the expression of each gene to ATP5B expression. For Delta1ext-IgG or γ-
secretase inhibitor L685 458 treatment effects on ECFCs, gene expression levels in non-
treated cells at day 0 were analyzed as controls. Results were expressed as a fold change (in 
logarithmic scale) compared with the control. The quantitative analysis was performed 
according to Pfaffl’s method [33]. The primer sequences are shown in Table II.
 Notch ligand and receptor cell surface expression on ECFCs
Relative levels of Notch ligands and receptors on ECFCs were determined by flow 
cytometry. ECFCs were harvested by cell dissociation buffer enzyme-free Hanks’-based 
reagent (Gibco). Cells (0.5×106) were suspended in staining buffer (PBS, 0.5% bovine 
serum albumin, and 2 mmol/L EDTA) and stained using purified anti-human Notch 4 (clone 
MHN4-2, BioLegend), biotinylated anti-human Notch 1 (clone mN1A, BioLegend), anti-
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human Dll1 conjugated to phycoerythrin (PE) (clone MHD 1–314, BioLegend), anti-human 
Delta-like protein 4 (Dll4) conjugated to allophycocyanin (APC) (clone MHD 4–46, Bio-
Legend) and anti-human CD31 antibody conjugated to PE-Cyanine7 (clone WM-59, 
eBiosciences) for 15 min at room temperature in the dark. After staining with purified and 
biotin conjugated primary antibodies, cells were stained with secondary antibody, goat anti-
mouse Alexa Fluor 488 (Invitrogen), Streptavidin-APC (eBiosciences) and with propidium 
iodide (PI) (eBiosciences) for 15 min at room temperature in the dark. For negative controls, 
we used fluorescence minus 1 (FMO) analysis, as we have previously described [28]. 
Stained cells were analyzed by FlowJo software.
 Western blot
Protein extracts were prepared as described previously [34], electrophoresed using sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis, transferred to nitrocellulose and probed 
with anti-human Coup TFII (clone H7147, R&D), anti-human Hey2 (ab167280Abcam) and 
anti-human β-actin (mAbcam 8226, Abcam). For Notch receptors, proteins were transferred 
to immobilon-P membrane, PVDF, 0.45 μm (Millipore), and probed with anti-human Notch 
1 (clone C-20, Santa Cruz Biotechnology), anti-human Notch 2 (clone 25–255, Santa Cruz 
Biotechnology) and anti-human Notch 4 (clone H-225, Santa Cruz Biotechnology).
 Implantation of human CB–derived ECFCs into NOD/SCID mice
Cellularized gel implants were cast as previously described [26,27]. Cultured ECFCs (2×106 
cells/mL) were suspended in a solution containing 1.5 mg/mL rat-tail collagen I (BD 
Biosciences Pharmingen), 100 μg/mL human fibronectin (Chemicon), 1.5 mg/mL sodium 
bicarbonate (Sigma), 25 mmol/L 4-(-2hydroxyethyl)-1-piperazineethanesulfonic acid 
(Cambrex), 10% fetal bovine serum, 30% serum free medium, pH-adjusted to 7.4. Then 250 
μL of the cell suspension was pipetted into 1 well of a 48-well tissue culture plate, allowed 
to polymerize at 37°C for 30 min, and covered with 500 μL SRM for overnight incubation at 
37°C, in 5% CO2. Gels were implanted into the flanks of anesthetized 6- to 9-week-old non-
obese diabetic (NOD)/severe combined immunodeficient (SCID) mice. After 14 days, the 
mice were sacrificed; the grafts were excised and analyzed by histology and 
immunohistochemistry (n = 6) as previously described [26,27]. ECFCs were also co-
implanted with OP9 or OP9-DL1 stromal cells in some studies. OP9-DL1 cells represent 
murine bone marrow stromal OP9 cells that have been engineered to constitutively express 
the Notch ligand Dll1 [35]. ECFCs and OP9 or OP9-DL1 were implanted at 4:1 ratios as 
above.
 Histology and immunohistochemistry
Sections were stained as previously described [27]. Briefly, paraffin-embedded tissue 
sections were deparaffinized and then either directly stained with hematoxylin and eosin 
(H&E) or immersed in retrieval solution (Dako) for 20 min at 90–99°C. Slides were 
incubated at room temperature for 30 min with anti-human CD31 antibody (clone JC70/A, 
Abcam), and rat anti-mouse smooth muscle α actin (αSMA) (clone 1A4, Sigma) followed 
by a 10-minute incubation with LASB2 link-biotin and streptavidin-HRP (Vector 
Laboratories), then developed with DAB (Vector Laboratories) solution for 5 min. Slides 
were analyzed by microscope under 40× magnification.
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 Assessment of apoptosis of ECFCs in 3-dimensional collagen gels
Apoptosis was assessed by examining the percentage of human CD31 positive ECFCs that 
bound annexin V and propidium iodide and was performed as per the manufacturer’s 
instruction (Apoptosis Detection kit, eBioscience). OP9 or OP9-DL1 cells were co-
implanted with ECFCs (1:1) in collagen gels at indicated time points as noted earlier. 
Collagen gels were prepared as described previously [27,36]. Briefly, 2×106 cells/mL were 
implanted in collagen solution with endothelial cell growth medium (EGM-2, Lonza). Gels 
were recovered from 1 to 3 days later and incubated in 250 μL Collagenase Type I (0.25%, 
Stemcell Technology) for 20 min at 37°C. Cell dissociation buffer was added to stop the 
enzymatic reaction (Invitrogen). Cells were centrifuged at 500 g for 5 min at room 
temperature. Cell pellets were suspended in staining buffer and stained with anti-human 
CD31 antibody conjugated to PE for 15 min (clone WM-59, BD Biosciences Pharmingen). 
Cells were incubated in binding buffer for 20 min and stained for Annexin V-APC and PI for 
30 min at room temperature in the dark. Stained cells were analyzed by FlowJo software.
 Caspase 1 and 3/7 assays in 3-dimensional collagen gels
Relative levels of active caspases 1 and 3/7 activities were determined by flow cytometry 
using fluorescein-labeled inhibitors of caspases (FLICA) reagent according to the 
manufacturer’s instructions (FLICA 660 caspase 3/7 assay kit and FLICA 660 in vitro 
caspase 1 detection kit, Immunochemistry Technology). Collagen gels and cells were 
prepared as previously described in assessment of apoptosis above. Cells recovered from 
gels were suspended in staining buffer and stained with anti-human CD31 antibody 
conjugated to PE (clone WM-59, BD Biosciences Pharmingen) for 15 min. Cells were 
incubated with the FLICA 660-DEVD-FMK caspse3/7 inhibitor/FLICA 660-YVAD-FMK 
caspase 1 inhibitor reagent for 20 min at room temperature in the dark. Unbound reagents 
were removed by two washes in wash buffer. The cells were stained with PI to assess 
viability. The cells were analyzed using a LSR II flow cytometer (BD Biosciences 
Pharmingen) and FlowJo software.
 Statistical analysis
Results are expressed as mean ± SEM for the study variables. The change of gene 
expression after rhVEGF-A, Delta1ext-IgG or γ-secretase inhibitor L685 458 induction in 
ECFC was assessed by Student’s paired t-test. The vessel number and size distribution were 
evaluated by Student’s unpaired t-test. A statistically significant difference was set at P < 
0.05. The quantification of Western blot data points, the number of smooth muscle α actin+ 
vessels, the assessment of apoptosis of ECFCs, and results of caspase 1 and 3/7 assays in 3-
dimensional (3D) collagen gels were assessed by 1-way analysis of variance, P < 0.05.
 Results
 Cultured human CB ECFCs express multiple Notch pathway transcripts
We examined cultured human CB ECFCs to determine if Notch ligand/receptor or 
downstream genes activated by Notch ligand binding were evident at baseline conditions, 
along with some typical endothelial transcripts. Cultured ECFCs expressed a variety of the 
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Notch pathway related transcripts and (Figure 1A). ECFCs displayed several typical 
endothelial cell surface markers such as platelet endothelial cell adhesion molecule-l (CD31) 
and vascular endothelial-cadherin (VE-Cad), which are typical of an EC identity and these 
cells have all been shown to give rise to cultures of ECs that display in vivo human vessel 
forming potential [27,37]. We also demonstrated protein expression of Notch ligands and 
Notch receptors on ECFCs by flow cytometry (Figure 1B). Although Dll1 was not detected 
on ECFCs, Notch 1 (2.7 ± 0.5%), Notch 4 (2.9 ± 0.3%) and Dll4 (4.6 ± 0.9%) were 
expressed on a subset of ECFCs (n = 3).
 Delta1ext-IgG induces known Notch downstream target gene transcripts in human CB 
ECFCs in a dose-dependent manner
Previous studies have indicated that Notch signaling is required for blood vessel formation 
during embryo development [4,6,38–40]. In this study, the engineered Notch ligand, 
Delta1ext-IgG, consisting of the extracellular domain of Dll1 fused to the Fc portion of 
human IgG, was used to activate Notch signaling in the ECFC. An enzyme-linked 
immunoabsorbent assay was used to confirm that the concentration of ligand coated on the 
tissue culture plate surface correlated with the amount of ligand bound as previously 
described (data not shown) [41]. The linear relationship between the amount of immobilized 
ligand and activation of Notch signaling was measured by the expression of the Notch 
downstream target gene Hey2 (Figure 2A,B). After 3 days of culture, cells were harvested 
and the expression of Hey2 was examined by quantitative PCR. Expression of Hey2 
increased as the concentration of Delta1ext-IgG increased, which indicated that human CB–
derived ECFCs were capable of responding to Notch ligand Dll1 stimulation.
We next evaluated whether Delta1ext-IgG influences other Notch related gene expression 
patterns in human CB ECFCs. Early passaged [2–4] ECFCs (n = 5) were cultured in wells 
coated with Delta1ext-IgG at concentrations ranging from 0.312 to 20 μg/mL or with the same 
concentration of human IgG as the control attachment ligand. ECFCs displayed a 
Delta1ext-IgG dose-dependent increase in Hes1 mRNA expression over 14 days of culture 
(data not shown), but Dll4, Notch 1 and Notch 4 mRNA were unchanged in the ECFC 
(online supplementary Figure 1). It is noteworthy that mRNA for the arterial-like endothelial 
gene markers Hey2 and Ephrin B2 were significantly upregulated after 3 days of 
Delta1ext-IgG induction at the concentration of 10 μg/mL (Figure 2B), whereas the 
expression of mRNAs for the venous-like endothelial gene markers Coup TFII and EphB4 
remained at low levels of detection (Figure 2B). Changes in Hey2 and Coup TFII gene 
expression at the transcript level upon Delta1ext-IgG binding were confirmed at the protein 
level (Figure 2C). Immunoblot analysis indicated that the protein level changes of Hey2 and 
Coup TFII were consistent with their mRNA levels of change. These results demonstrated 
that Delta1ext-IgG was able to enhance Notch-related gene expression in human CB ECFCs 
in vitro.
Next, we examined whether Delta1ext-IgG-induced EphrinB2 expression could be suppressed 
if the Notch signaling pathway was blocked via the use of a γ-secretase inhibitor L685458. 
The expression of Hes1 and Hey2 mRNA decreased with the addition of the inhibitor to the 
culture (online supplementary Figure 2A,B). Interestingly, the Delta1ext-IgG-induced 
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upregulation of mRNA for Hey2 and EphrinB2 was significantly decreased in the presence 
of 1 μmol/L L685458 for 3 days, whereas the expression of mRNA for Coup TFII was 
noticeably increased (supplementary Figure 2C). In addition, when control human CB 
ECFCs were treated with 1 μmol/L L685458 alone for 3 days, the expression of mRNAs for 
Hey2 and EphrinB2 were dramatically suppressed, whereas the mRNA for Coup TFII was 
considerably enhanced when compared to Deltaext-IgG treated cells (supplementary Figure 
2C). Collectively, these observations demonstrated that immobilized Dll1 activated Notch 
signaling is able to regulate ECFC gene expression patterns in vitro over several days of 
exposure.
 Dll1 expression by OP9 stromal cells significantly enhances in vivo postnatal 
vasculogenesis
We subsequently tested whether human CB ECFCs exposed to immobilized Dll1 
(Delta1ext-IgG) would increase vasculogenesis after they were implanted in vivo. ECFCs 
were treated with 10 μg/mL of Delta1ext-IgG for 3 days in vitro, then suspended in a 
collagen-fibronectin matrix and subcutaneously implanted into immunodeficient mice as 
described [27]. After 14 days, the mice were euthanized, the grafts were harvested, and 
implants analyzed for blood vessel formation (supplementary Figure 3A). Our data indicated 
that in vitro Delta1ext-IgG-primed human CB ECFCs were unable to enhance vessel 
formation in vivo because the total vascular area of the human vessels was unchanged 
compared to IgG control cultured cells (supplementary Figure 3B,C). These data indicate 
that preconditioning of ECFC in vitro with Notch activation fails to translate into enhanced 
vasculogenic properties in ECFC in vivo.
Knowing that activation of Notch signaling is mediated by cell–cell interaction between 
Notch ligands and receptors in vitro and in vivo [5], we hypothesized that co-implantation of 
ECFCs with stromal cells constitutively expressing Dll1 may be required to enhance 
vasculogenesis in vivo. ECFCs were cultured in standard conditions and then co-implanted 
with OP9-Delta-like 1 stromal cells (OP9-DL1) into immunodeficient mice. After 14 days, 
the mice were euthanized, and the grafts were harvested and investigated for human blood 
vessel formation. Use of a specific anti-human CD31 antibody revealed that human CB 
ECFCs were able to form microvessels perfused with murine red blood cells in the grafts 
(Figure 3A). Of interest, the vessel number and morphology differed between the collagen 
gel matrices containing ECFC co-implanted with OP9-DL1 (ECFC/OP9-DL1) cells and the 
control implants (the collagen gels containing ECFC alone or ECFC with OP9 [ECFC/
OP9]). The quantification of murine erythrocyte-containing human microvessels (Figure 3B) 
revealed a significantly greater number of hCD31+ vessels were present in ECFC/OP9-DL1 
implants compared with the controls (ECFC alone versus ECFC/OP9 versus ECFC/OP9-
DL1 was 30.03 ± 8.14 versus 53.32 ± 7.19 versus 129.10 ± 27.80 vessels/mm2, respectively, 
P < 0.05). In addition, the size distribution of hCD31+ microvessels was altered with the 
ECFC/OP9-DL1 implants compared with the control implants (Figure 3C). Noticeably, upon 
Dll1 stimulation, human CB ECFCs gave rise to significantly more large area microvessels 
(1000–4000 μm2) and fewer small ones (51–100 μm2; Figure 3C). Furthermore, the average 
vessel area was distinctly increased with the ECFC/OP9-DL1 implants compared to the 
control implants (Figure 3D, ECFC alone versus ECFC/OP9 versus ECFC/OP9-DL1 was 
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223.81 ± 15.47 versus 266.03 ± 39.28 versus 384.61 ± 42.73 μm2, respectively, P < 0.05). 
These alterations resulted in the overall hCD31+ vascular area (= average vessel density × 
average vessel area) being significantly enhanced in the ECFC/OP9-DL1 implants compared 
with the control implants (Figure 3E).
Notch 1 and Notch 2 protein levels were significantly upregulated in implants with OP9-
DL1, but Notch 4 expression level was distinctly decreased (Figure 3F). In addition, 
stimulation with the OP9-DL1 Notch ligand, caused rapid nuclear translocation of the 
cleaved domain of Notch 1 [16] and was widely detected in implants containing ECFC and 
OP9-DL1 (specific EC nuclear immunostaining for cleaved 1 [Val1744; Figure 3G]). This 
observation indicated that human ECFC-derived vessels were responsive to Dll1 ligand 
presentation in vivo and Notch 1 signaling was persistently activated in ECFC/OP9-DL1 
implants in vivo. Also, anti-mouse smooth muscle α actin antibody staining (red) was 
detected in perivascular cells located around human ECFC-derived CD31+ (brown) 
microvessels in co-implants with OP9-DL1 (Figure 3H). Together, these data suggest that 
Dll1 binding to Notch 1 significantly modulates vasculogenesis in vivo by inducing Notch 
signaling and promoting more ECFC-derived vessel formation with an overall enlarged 
vascular area and recruited host murine perivascular cells to the human vessels.
 Dll1 expressed by OP9 stromal cells significantly reduces apoptosis of human CBECFCs 
in 3-dimensional collagen gels
To begin to understand the mechanisms through which Notch activation could enhance 
vasculogenesis of the human ECFC, we first examined whether the presence of OP9-DL1 
co-implantation altered ECFC proliferation in the collagen gels and observed no effect (data 
not shown). We then tested whether the presence of OP9-DL1 decreases apoptosis of human 
CB ECFCs in the 3D collagen implants. After 1, 2, 3 or 5 days, the cells were recovered and 
assessed for apoptosis of ECFCs using AnnexinV and propidium iodide staining. Implanted 
ECFCs started undergoing apoptosis on day 1, and a significant majority of the cells died on 
day 2 and 3 after implantation (Figure 4A). We investigated whether a higher cell density of 
ECFC (3–6×106 cells/mL) might improve cell survival in the collagen gels and observed the 
increased cell density caused more apoptosis and no significant increase in vessel number or 
area (data not shown). In contrast, ECFC co-implanted with OP9-DL1 (1:1 cell ratio) 
revealed a significantly higher percentage of the AnnexinV−/PI− viable cell population 
compared with ECFC alone or ECFC with OP9 implantation on day 1 and 3 (Figure 4B,C). 
These results indicated that co-implantation of ECFC with OP9-DL1 stromal cells increased 
survival of ECFC within the 3D collagen gels. Because caspase activation is a hallmark of 
apoptosis, we examined ECFC for evidence of caspase activation within the 3D gels. The 
caspase assay we used detected fluorescein-labeled inhibitors that bind to activated caspases 
1 and 3/7 within cells. The inhibitors bind with 1:1 stoichiometry to the active centers of 
activated caspases. Thus, the assay can be used for quantitative analysis of the activated 
caspases in the cells. In every experiment performed, the caspase 3/7−/PI− cell subset of 
ECFC co-implanted with OP9-DL1 was significantly higher on day 3 compared to 
implanted ECFC alone or ECFCs with OP9 implantation (Figure 4D). ECFC co-implanted 
with OP9-DL1 also displayed a greater percentage of caspase 1−/PI− cells compared to 
ECFC alone or ECFC with OP9 implantation on day 2 and 3 (Figure 4E). These 
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observations indicate that Notch activation by OP9-DL1 stromal cells reduced activated 
caspase 3/7 and caspase 1 within ECFCs in collagen gels. Therefore, we conclude that 
Notch activation of ECFC in collagen gel implants enhanced survival of ECFCs by reducing 
activation of caspase 3/7 and caspase 1.
 Discussion
Vasculogenesis is the process of primary capillary plexus formation from angioblasts during 
embryogenesis. Remodeling of the capillary plexus normally occurs via angiogenesis and 
arteriogenesis to form the hierarchical mature systemic vasculature [42,43]. It has been well 
established that Notch signaling plays an important role in regulating vascular patterning and 
remodeling during development [44–49] and after birth [7,24]. Previous studies in murine 
embryonic development showed that ectopic Notch 1 activation in ECs [45,46] caused 
vascular remodeling defects with enlarged vessel caliber. In contrast, small-sized vessels 
were present upon loss of active Notch signaling [46,47]. We report that the in vivo presence 
of stromal cell associated Notch ligand Dll1 led to enhanced vasculogenesis and vascular 
remodeling in human CB ECFCs, characterized by increased vessel density and enlarged 
vessel area (Figure 3). Accordingly, our observations coincide with the previous studies 
indicating that Dll1-dependent Notch 1 signaling regulates vessel size and state in murine 
embryogenesis.
A role for MSCs in promoting enhanced human ECFC vasculogenesis in vivo has been 
reported by several laboratories [50–57]. Indeed, conditioned medium secreted by multiple 
tissue–derived cultured MSCs promotes ECFC vasculogenesis in vivo, although the specific 
molecules promoting enhanced ECFC function remain elusive [55]. Surprisingly, we did not 
find a significant improvement in ECFC vasculogenic properties when the murine OP9 MSC 
were co-implanted with the ECFC in our studies. We speculate that differences in the types 
and composition of the 3D scaffolding proteins and strain of immunodeficient mice may 
play a role in the extent to which MSC promote human ECFC vasculogenesis in vivo. 
Although there are numerous matrices that permit ECFC and MSC, but not ECFC alone, to 
form vessels in vivo upon implantation into nude mice [52,58], CB ECFCs alone form 
human blood vessels in tissue engineered skin substitutes implanted in C.B-17 SCID/beige 
mice [59] or in type I collagen matrices implanted in NOD/SCID mice [26,27]. Further work 
to compare ECFC vasculogenesis directly in various matrices in several different 
immunodeficient murine hosts will be required to address the discrepancies in the literature.
VEGF plays a critical role in determining arterial-venous specification and the concentration 
of VEGF influences this determination [60]. In cultured murine ESCs, a high concentration 
of VEGF (50 ng/mL) drove an arterial-like endothelial gene expression pattern, whereas a 
low dose encouraged venous-like endothelial gene expression [60]. Similarly, addition of 
100 ng/mL of rhVEGF-A to cultured cells upregulated an arterial-like endothelial gene 
expression pattern in hMAPCs and in hMSCs [61,62]. Recently, in the presence of 50 ng/mL 
of rhVEGF-A, arterial-like endothelial genes and downstream genes of Notch signaling were 
increased in cultured ECFCs [63]. The arterial-like endothelial genes induced by VEGF 
were decreased with treatment using γ-secretase inhibitor on cultured ECFCs [63]. This 
study indicated that VEGF-dependent induction leads to arterial-like gene expression with 
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Notch pathway signaling activation. Our results consistently confirmed previous work that 
rhVEGF-A at 50 ng/mL was sufficient to enhance expression of the arterial-like endothelial 
genes with activation of Notch in cultured CB ECFC (data not shown). In addition, Notch 
stimulated preconditioning in vitro was able to induce an arterial-like gene expression 
pattern in vitro (data not shown). However, preconditioning of ECFC in vitro with Notch 
stimulation failed to promote an arterial-like phenotype (data not shown) in vivo, suggesting 
that in vitro priming is not sufficient for in vivo specification in our experimental model. Of 
interest, in vivo co-implantation of OP9-DL1 stromal cells with ECFCs significantly 
enhanced vasculogenesis in vivo by promoting more ECFC-derived vessel formation with an 
overall enlarged vascular area and recruiting of murine perivascular cells around ECFC-
derived vessels (Figure 3). Shepherd et al. [64] reported that co-implantation of human aortic 
smooth muscle cells promoted larger vessel size with periendothelial investment at 60 days 
post-implantation. Although we implanted the OP9-DL1 stromal cells with the ECFC, we 
observed an effect of Notch activation on human vessel size and recruitment of host 
perivascular cells. Future studies using specific perivascular cell subsets may indicate 
whether there are cell specific influences provided by different mesenchymal cell subsets on 
the human ECFC.
In the present work, implanted human CB ECFCs started undergoing apoptosis on day 1. 
After 2–5 days of implantation, most implanted ECFCs died with only 5–8% of total 
implanted cells persisting as perfused vessels (data not shown). Previous studies have 
indicated that human ECFC-lined vessels formed within subcutaneous implants in mice 
were found as early as day 1 or 2 following implantation, but these lumenized structures 
lacked significant perfusion with murine red blood cells at those early time points. However, 
ECFC-derived vessels perfused with host murine red blood cells (perfusion also confirmed 
by human specific lectin infusion and contrast-enhanced ultrasound flow detection) were 
detected after 3–4 days of implantation in vivo [52]. Thus, implanted endothelial cells had to 
survive at least 3–4 days in vivo to be able to contribute to a stable perfused capillary 
network. Given the proclivity of capillary networks to destabilize and regress with 
endothelial apoptosis in the absence of periendothelial support cells or adhesion of the 
endothelial cells to matrix proteins via cell surface integrin receptors [65–68], understanding 
the importance of a balance of pro-apoptotic versus anti-apoptotic signals in the plasticity of 
the capillary plexus has become an important paradigm. Perivascular support cells can 
induce endothelial cells to secrete basement membrane proteins that enhance endothelial cell 
integrin mediated attachment and increases in bcl-2 expression to protect cells from 
apoptosis [67,69]. HUVECs undergo apoptosis when implanted in immunodeficient mice 
within 24h, whereas Bcl-2 overexpression in HUVECs rescues them from apoptotic death 
and enhances the number and complexity of human vessels formed [70]. Bcl-2 
overexpression in HUVECs also increases the number of human and mouse endothelial cell-
lined vessels (vascularization) in implants and induces maturation of vessels by increasing 
tissue perfusion [59,71]. The frequency of the AnnexinV−/PI− viable cell population and 
overall hCD31+ vascular area in the ECFC/OP9-DL1 implants reflected a four-fold increase 
compared with the ECFC/OP9 implants (Figures 3E and 4C), suggesting a direct effect 
between diminishing apoptosis and increased vessel formation by Notch activation in ECFC 
in vivo. Our results suggest that improvement of cell survival of ECFCs by Dll1-dependent 
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Notch 1 signaling activation (Figure 3F) leads to vessel stabilization and promotes 
functional vessel formation in 3D collagen gels.
In summary, we have demonstrated that human CB ECFCs robustly form microvessels 
exhibiting a distinct remodeling pattern with increased vessel number and enlarged vessels 
by diminishing apoptosis of CB ECFCs during OP9-DL1 mediated Notch activation. 
Although other studies have shown that stromal cell co-implantation with ECFCs increases 
vessel number and maturation in vivo [53,72], we did not observe any enhancement of 
vasculogenesis by co-implanting ECFCs with OP9 stromal cells. However, co-implantation 
of OP9-DL1 led to constitutive ECFC Notch activation and resulted in greater numbers and 
maturation of human blood vessels in vivo. Further studies to present Notch activating 
ligands embedded within the matrix molecules may permit the modulation of human vessel 
formation using ECFC alone.
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Figure 1. 
The expression of Notch pathway related transcripts in cultured ECFCs. (A) Human CB–
derived ECFCs expressed numerous Notch pathway related transcripts and EC gene markers 
such as platelet endothelial cell adhesion molecule-l and VE-Cadherin. (B) Notch ligands 
and receptors were expressed on a subset of ECFCs. The representative histograms show 
comparison between fluorescence minus one (FMO) control (gray) and Notch molecule 
expression (black) on the surface of ECFCs.
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Figure 2. 
ECFCs respond to Notch signaling with increased expression of known downstream target 
genes (n = 3). The dose-dependent activation of endogenous Notch signaling in human CB–
derived ECFCs is indicated by Hey2 (A) expression after 3 days of incubation in various 
concentrations of Delta1ext-IgG. (B) Quantitative RT-PCR analysis revealed Hey2 and 
EphrinB2 transcripts were significantly increased after 3 days of stimulation with 10 μg/mL 
Delta 1ext-IgG, whereas the expression of Coup TFII and EphB4 were not significantly 
affected. Expression levels were presented as a fold change (in logarithmic scale) compared 
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with baseline levels and were normalized by using ATP5B as a housekeeping gene. The 
expression at day 0 in nontreated cells served as a baseline value. n = 5. *P < 0.05. (C) 
Upper panel depicts representative immunoblots of Hey2 and Coup TFII proteins and lower 
panel reveals quantification (protein expression levels were normalized by using β-actin). *P 
< 0.05. HUAEC, human umbilical artery endothelial cells; HUVEC, human umbilical vein 
endothelial cells.
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Figure 3a
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Figure 3b
Figure 3. 
In vivo Dll1 stimulation boosts the formation of functional vessels (n = 3). (A) Anti-human 
CD31 staining identified human CB–derived ECFCs, alone or combined with OP9 or OP9-
DL1, that have formed microvessels in collagen gels after 14 days of implantation. Upon the 
stimulation of Dll1, there was a significant increase in the number of vessels formed by 
human CB–derived ECFCs and perfused with murine red blood cells per mm2 in the gel (B). 
In addition, the size distribution of hCD31+ microvessels was noticeably altered (C), 
shifting toward larger-sized vessels (1001–4000 μm2) with Dll1 stimulation. Moreover, 
vessel morphology was significantly altered by the presence of Dll1 with increased average 
vessel area (D) and total vascular areas (E). (F) Upper panel shows representative 
immunoblots of Notch 1, Notch 2 and Notch 4 proteins and lower 2 panels show 
quantification of repeated experiments (protein expression levels were normalized using β-
actin); n = 3. *P < 0.05. Anti-cleaved Notch 1 (Val1744) antibody staining (G) in endothelial 
nuclei confirms that the activation of Notch 1 is detected in vivo in newly formed human 
vessels in the presence of Dll1; n = 6. Scale bar represents 100 μm. (H) Anti-mouse smooth 
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muscle α actin (αSMA) antibody staining (red) was detected in perivascular cells around 
human ECFC–derived CD31+ vessels (brown) in implants with OP9-DL1 stromal cells. 
Scale bar represents 10 μm. *P < 0.05; **P < 0.001; ***P < 0.0001.
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Figure 4. 
OP9-DL1 stimulation diminishes apoptosis of ECFCs in collagen gels (n = 5). (A) 
Representative dot plots of apoptosis analysis of ECFCs at 30 min or on days 1–3. (B) 
Representative dot plots of apoptosis analysis of ECFC alone, co-implanted with OP9, or 
OP9-DL1 on days 1–3. (C) The Annexin−/PI− viable population of ECFC co-implanted with 
OP9-DL1 was significantly higher on day 1 and 3 compared with implantation of ECFC 
alone or ECFC with OP9 on day 1 and 3. (D) The percentage of the Caspase 3/7−/PI− 
population of ECFC co-implanted with OP9-DL1 was significantly greater compared with 
ECFC alone or with OP9 on day 3. (E) ECFC co-implanted with OP9-DL1 displayed a 
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higher percentage of Caspase 1−/PI− cells compared with ECFC alone or ECFC with OP9 
co-implants. n = 6. *P < 0.05.
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Table I
Primers used for conventional RT-PCR.
Gene Forward Reverse Tm Product size (bp)
VEGFR1 AGTTTAAAAGGCACCCAGCA ACGAGCTCCCTTCCTTCAGT 55 362
VEGFR2 GAGGGACTTGGACTGGCTTT GATTTGAAATGGACCCGAGA 55 302
VEGFR3 TGAACATCACGGAGGAGTCA TCAGGCTTGTTGATGAATGG 55 337
NRP1 GAAAAATGCGAATGGCTGAT AATCCGGGGGACTTTATCAC 53 335
NRP2 CAAACACTGTGGGAACATCG TGTCCAGCCAATCGTACTTG 55 338
DLL1 TGTGCCTCAAGCACTACCAG ACACACGAAGCGGTAGGAGT 55 353
DLL4 TATTGGGCACCAACTCCTTC ACATAGTGGCCGAAGTGGTC 55 349
NOTCH 1 GGCCAGAACTGTGAGGAAAA GCAGTAGAAGGAGGCCACAC 57 327
NOTCH 4 TCTCCCTCTCCATTGACACC TGGAAGCACTCGTTGACATC 55 323
HEY2 TGGGGAGCGAGAACAATTAC GCACTCTCGGAATCCTATGC 55 329
EFNB2 (C) TTATTTGCCCCAAAGTGGAC CCTGGTTGATCCAGCAGAAC 55 347
EPHB4 GAGCTGTGTGGCAATCAAGA ACTTTGCAGACGAGGTTGCT 55 345
COUP TFII AACACATCGAGTGCGTGGT CAGGTACGAGTGGCAGTTGA 55 311
PECAM1 GCAAAATGGGAAGAACCTGA ACAGTTGACCCTCACGATCC 55 316
VECAD TGGACAAGGACACTGGTGAA TCTTGCAGAGTGACCAGCAC 55 382
ACTB GCCAGCTCACCATGGATGAT GTCTCAAACATGATCTGGGTC 57 388
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Table II
Primers used for quantitative RT-PCR.
Gene Forward Reverse Eff
VEGFR1 GCTTCTGACCTGTGAAGCAA CTCGTGTTCAAGGGAGTGGT 1.987
VEGFR2 GAACATTTGGGAAATCTCTTGC CGGAAGAACAATGTAGTCTTTGC 1.917
VEGFR3 AGACAAGAAAGCGGCTTCAG TTGGGAGTCAGGGTGTGC 1.860
NRP1 GTTGTGTCTTCAGGGCCATT AATCCGGGGGACTTTATCAC 2.036
NRP2 TCTGCGCTACGAGATCTTCA GTGCAGTCCAAGTTGTGTGG 1.862
DLL4 GACCACTTCGGCCACTATGT TTGCTGCAGTAGCCATTCTG 1.967
NOTCH 1 CTTCAATGACCCCTGGAAGA GAAGTGGAAGGAGCTGTTGC 1.950
NOTCH 4 CTGCTGCTGCTGCTATGTGT GTCAGGAAACTGGCACGTCT 1.833
HES1 TGCTTCACTGTCATTTCCAGA GAAAGTCTGAGCCAGCTGAA 1.958
HEY2 CTTGTGCCAACTGCTTTTGA TCATGAAGTCCATGGCAAGA 1.912
EFNB2 TCTTTGGAGGGCCTGGAT CCAGCAGAACTTGCATCTTG 1.986
EPHB4 TTTGGCTCCTTCGAGCTG GGCCAAGATTTTCTTCTGGTG 1.880
COUP TFII CCAAGAGCAAGTGGAGAAGC TCCACATGGGCTACATCAGA 1.988
ATP5B CCACTACCAAGAAGGGATCTATCA GGGCAGGGTCAGTCAAGTC 1.960
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